-+ 0.00%
-+ 0.00%
-+ 0.00%
GSK's Ris-Rez achieves 61% response rate at 8 mg/kg in early-stage lung cancer trial
Share
Listen to the news
GSK's Ris-Rez achieves 61% response rate at 8 mg/kg in early-stage lung cancer trial
  • GSK announced positive antitumor activity with a manageable safety profile for investigational Ris-Rez in relapsed extensive-stage small cell lung cancer.
  • Phase Ib findings supported selection of the higher dose for the ongoing global phase III EMBOLD SCLC-301 trial.
  • Results will be presented at the European Society for Medical Oncology Congress 2026 in Madrid, Spain.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GSK plc published the original content used to generate this news brief on October 18, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending